Psyence Biomedical Amends Financing Agreement, Adds Intraday Share Sale Mechanism
PBM has more than doubled off its 52-week low of $1.92 on elevated volume (27× avg).
Summary
Psyence Biomedical Ltd. amended its Common Stock Purchase Agreement with White Lion Capital, LLC, introducing a new 'Intraday Purchase Notice' mechanism for selling shares up to 5% of daily trading volume at market-determined prices.
Key Events · Financing and Capital Events · PBM
-
Amended Financing Agreement
The company entered into Amendment No. 3 to its Common Stock Purchase Agreement with White Lion Capital, LLC, originally dated July 25, 2024, and previously amended.
-
Introduced Intraday Purchase Mechanism
A new 'Intraday Purchase Notice' mechanism allows the company to sell common shares to White Lion Capital, LLC, during the Commitment Period.
-
Daily Sale Limit
The number of shares sold via an Intraday Purchase Notice cannot exceed five percent (5%) of the Average Daily Trading Volume.
-
Market-Based Pricing
The purchase price for shares sold under this mechanism will be the lowest traded price of the common shares during a one-hour valuation period, subject to a specified floor price.
Analysis · PBM · Life Sciences
Psyence Biomedical Ltd. has updated its existing Common Stock Purchase Agreement with White Lion Capital, LLC, introducing a new 'Intraday Purchase Notice' mechanism. This provides the company with a flexible, on-demand method to raise capital by selling shares to White Lion Capital, LLC. While this offers a crucial financing lifeline for a micro-cap company, the terms allow for sales at the lowest traded price during a one-hour valuation period, which could result in significant dilution for existing shareholders. Investors should monitor the frequency and volume of sales under this new mechanism, as it represents a potential overhang on the stock price.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.3% of the 1681 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBM was trading at $14.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8M. The 52-week trading range was $1.92 to $74.94. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.